泽布替尼仿制药不得在2037年之前销售,百济神州与MSN达成专利和解

医药魔方Info
20 Nov 2024

11月19日, 百济神州 宣布已与MSN Pharmaceuticals和MSN Laboratories Private公司达成了和解协议,解决了与MSN在美国提交的Brukinsa(泽布替尼) 仿制药 注册申请(ANDA)相关的专利诉讼问题。根据协议条款,MSN将无法在2037年6月15日之前销售Brukinsa的仿制药,但在某些惯例情况下,该日期可能会提前或延后。MSN在诉讼中并未对...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10